In cystic fibrosis, a genetic condition that has a high population of young patients with multiple medical treatment needs, it is of clinical importance to ensure treatment compliance to avoid premature death. Behavioral economics can help here by addressing how we improve motivation and the perceived value of medical treatments, to improve overall patient compliance. Regarding treatment adherence in children, up to 70% of patients with chronic diseases have poor adherence (Haynes RB, 2002). Poor adherence to cystic fibrosis therapies can lead to an increase in disease symptoms, a decrease in physical functioning, an increase in hospital stay, morbidity and mortality rates, and consequently an increase in healthcare costs (Vibeke Bregnballe , 2011). Therefore, the higher the compliance, the more convenient the treatments become and the healthier the patients stay. It is also important to note that every missed medication represents a financial loss. The Capgemini Group reported in 2013 that the global cost of non-adherence is estimated at $564 billion. So if we have children...